These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34590580)

  • 1. Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion.
    Harada A; Matsumoto S; Yasumizu Y; Shojima K; Akama T; Eguchi H; Kikuchi A
    Elife; 2021 Sep; 10():. PubMed ID: 34590580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target.
    Fujii S; Matsumoto S; Nojima S; Morii E; Kikuchi A
    Oncogene; 2015 Sep; 34(37):4834-44. PubMed ID: 25486429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
    Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
    J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma.
    Fujii S; Shinjo K; Matsumoto S; Harada T; Nojima S; Sato S; Usami Y; Toyosawa S; Morii E; Kondo Y; Kikuchi A
    Oncotarget; 2016 Dec; 7(49):81571-81587. PubMed ID: 27835592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth.
    Harada T; Matsumoto S; Hirota S; Kimura H; Fujii S; Kasahara Y; Gon H; Yoshida T; Itoh T; Haraguchi N; Mizushima T; Noda T; Eguchi H; Nojima S; Morii E; Fukumoto T; Obika S; Kikuchi A
    Mol Cancer Ther; 2019 Mar; 18(3):602-612. PubMed ID: 30647122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer.
    Hu Q; Masuda T; Sato K; Tobo T; Nambara S; Kidogami S; Hayashi N; Kuroda Y; Ito S; Eguchi H; Saeki H; Oki E; Maehara Y; Mimori K
    Ann Surg Oncol; 2018 Mar; 25(3):745-753. PubMed ID: 29270876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARL4C might serve as a prognostic factor and a novel therapeutic target for gastric cancer: bioinformatics analyses and biological experiments.
    Xie N; Bai Y; Qiao L; Bai Y; Wu J; Li Y; Jiang M; Xu B; Ni Z; Yuan T; Shi Y; Wu K; Xu F; Wang J; Dong L; Liu N
    J Cell Mol Med; 2021 Apr; 25(8):4014-4027. PubMed ID: 33724652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
    Kimura K; Matsumoto S; Harada T; Morii E; Nagatomo I; Shintani Y; Kikuchi A
    Cancer Sci; 2020 Mar; 111(3):951-961. PubMed ID: 31925985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; CaƱamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARF6 and AMAP1 are major targets of
    Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
    Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYRI-B-mediated macropinocytosis drives metastasis via lysophosphatidic acid receptor uptake.
    Nikolaou S; Juin A; Whitelaw JA; Paul NR; Fort L; Nixon C; Spence HJ; Bryson S; Machesky LM
    Elife; 2024 May; 13():. PubMed ID: 38712822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
    Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
    Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells.
    Assi M; Achouri Y; Loriot A; Dauguet N; Dahou H; Baldan J; Libert M; Fain JS; Guerra C; Bouwens L; Barbacid M; Lemaigre FP; Jacquemin P
    Cancer Res; 2021 May; 81(10):2679-2689. PubMed ID: 33602788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic significance of Arl4c expression in colorectal cancer.
    Chen X; Su Z; Wang S; Xu H
    Cancer Biomark; 2016; 16(2):253-7. PubMed ID: 26756615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.